Life Sciences Tools and Services

WuXi Biologics

WuXi Biologics Chengdu Base Completed, Targeting GMP Production by End-2026

WuXi Biologics Chengdu Microbial Commercialization Facility Achieves Structural Completion and Arrival of Key Equipment

WuXi Biologics' Three Factories in Wuxi Obtain Korean GMP Certification

WuXi Biologics Reaches Sixth Consecutive Morningstar ESG Leadership Rating

WuXi Biologics Obtains ISO 13485:2016 Certification

CMBI Raises Goal Price for Wuxi Biologics to HKD 39

CICC Raises Profit Forecast for Wuxi Biologics and Maintains 'Outperform' Rating

BofA Securities Downgrades WuXi Biologics' Revenue Forecast and Target Price

WuXi Biologics Approves Granting Restricted Stock Awards to Employees

Nomura Releases Report on Wuxi Biologics' Performance and Forecast

WuXi Biologics released FY2025 9 Months earnings on March 24 (EST), actual revenue USD 2.21 B, actual EPS USD 0.2401

WuXi Biologics released FY2025 Q3 earnings on March 24 (EST), actual revenue USD 831.31 M, actual EPS USD 0.0855

WuXi Biologics released FY2025 Q4 earnings on March 24 After-Market EST, actual revenue USD 845.97 M, actual EPS USD 0.087

WuXi Biologics released FY2025 earnings on March 24 After-Market EST, actual revenue USD 3.054 B (forecast USD 3.141 B), actual EPS USD 0.3253

WuXi Biologics reports non-GAAP EPS of ¥1.33, revenue of ¥21.79 million

WuXi Biologics Reports 45.3% Increase in Net Profit to RMB 5.733 Billion in 2025 Fiscal Year

WuXi Biologics to Release FY2025 Earnings on March 24 After-Market EST, Forecast Revenue USD 3.199 B

WuXi Biologics Signs Strategic Collaboration Agreement with Earendil Labs

Nichi Xia Cheng B-Type Private Plc Issues 84,033,600 Shares to Wuxi Biologics HealthCare Venture

BlackRock Reduces Stake in Wuxi Biologics H-shares to 4.51%

Amesite

Meiwu Tech

InMed Pharmaceuticals

Co-Diagnostics

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

NextNRG

MetaVia

Phoenix Asia

Generation Income Properties

Virax Biolabs

02268

WXXWY

02269

159615

Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.

prnewswire

WUXI XDC

WUXI BIO

Sanofi

iShares US Pharma

China Southern Hang Seng Biotech ETF(QDII)

Ark Genomic Revolution ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

VG Health

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

SPDR S&P Biotech

Minsheng Royal CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

iShares Biotechnology ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Guotai CSI Bio-medicine ETF

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

02509

603259

02359

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

AASTOCKS News

QYUNS-B

WuXi AppTec

WUXI APPTEC

SKB BIO

TEDA BIOMEDICAL

INNOVENT BIO

ICBCCS SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

Citi's research report highlights ongoing improvements in China's healthcare sector, driven by innovative drugs and CDMOs. Key segments have stabilized, with sales of innovative drugs accelerating and record CXO order volumes. Upcoming catalysts include data releases and licensing momentum. Citi updated its Hong Kong Buy list, featuring top picks WUXI APPTEC, WUXI BIO, and ALI HEALTH, while noting sector-specific challenges have been largely absorbed by the market.

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Universal 800 Health Care ETF

Hwabao WP CSI Pharmaceuticals ETF

Citigroup

ALI HEALTH

HENGRUI PHARMA

Hengrui Pharma

CSPC PHARMA

ASCLETIS-B

MircroPort Medbot-B

Mindray

Aier

Yifeng Pharmacy

CR MEDICAL

Bloomage Biotech

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Citi: Fundamentals of China Healthcare Sector Continue to Improve; Top Picks WUXI APPTEC , WUXI BIO , ALI HEALTH

WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) experienced a significant decline in short interest, dropping 82.6% to 24,485 shares as of April 15th. The short-interest ratio is currently 0.2 days, with approximately 0.0% of shares sold short. The stock traded at $8.54, with a 12-month range of $5.50 to $11.21. WuXi Biologics specializes in biologics as a global contract research and manufacturing organization, offering services across the biologics value chain.

Market Beat

WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Short Interest Update

WuXi Biologics has announced the structural completion and arrival of key equipment at its microbial commercial manufacturing site in Chengdu. This site, covering 95,000 square meters, aims for GMP production by the end of 2026 and will support the manufacturing of various biologics. It features advanced capabilities, including a 15,000 L fermenter and China's first dual-chamber lyophilization line. The site emphasizes efficiency, sustainability, and integrated automation, enhancing WuXi's end-to-end CRDMO services for global pharmaceutical innovators.

VISEN PHARMA-B

07:03 ETWuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival

WuXi Biologics has received GMP certification from South Korea's MFDS for three of its manufacturing facilities, enabling commercial production of bispecific antibody therapeutics for biliary tract cancer. The certification confirms the company's compliance with global quality standards and enhances its manufacturing capabilities in the Asia-Pacific region. CEO Dr. Chris Chen emphasized the importance of this certification in supporting clients and accelerating the delivery of innovative biologics. WuXi Biologics operates 15 GMP-certified facilities globally and has a strong track record of regulatory compliance and quality assurance.

02:14 ETWuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics

WuXi Biologics (SEHK:2269) has secured ISO 13485:2016 certification for its medical device quality management system, highlighting its commitment to quality and compliance. The company's share price is currently HK$37.18, with a 1-month return of 6.41% and a year-to-date return of 14.26%. Analysts suggest the stock is undervalued, with a fair value estimate of HK$45.08, indicating a potential 38% intrinsic value gap. The company is positioned for growth in the biologics sector, but faces geopolitical risks that could impact its performance.

Simplywall

A Look At WuXi Biologics (SEHK:2269) Valuation After Securing ISO 13485:2016 Certification

WuXi Biologics(WXXWY.US)